<DOC>
	<DOCNO>NCT01060137</DOCNO>
	<brief_summary>The purpose study evaluate usefulness fentanyl matrix assess patient ' satisfaction administrate fentanyl matrix , background pain treatment , breakthrough pain treatment lung cancer patient complain pain . Fentanyl matrix design deliver medication nearly constant amount per unit time body skin 3 day ( 72 hour ) .</brief_summary>
	<brief_title>Fentanyl Matrix Lung Cancer Pain</brief_title>
	<detailed_description>This study open-label , single-arm , multicenter , prospective study evaluate usefulness fentanyl matrix ( fentanyl transdermal patch-type system ) assess patient satisfaction administrate fentanyl matrix ( background pain treatment , breakthrough pain treatment ) patient lung cancer 21 day . Fentanyl transdermal patch-type system design deliver medication nearly constant amount per unit time body skin 3 day ( 72 hour ) . Studies transdermal fentanyl find analgesic effect malignant pain , patient receive medication prefer fentanyl experienced less constipation . Safety assessment include adverse event monitoring , vital sign , laboratory work . start 12.5g/h 25g/h fentanyl matrix transdermally investigator 's discretion flexible dose depend patient 's pain relief 3 week</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Fentanyl</mesh_term>
	<criteria>Patients histologically confirm lung cancer , complain cancer pain Patients take Ultracet , Tramadol , Codeine ( Codeine combination drug ) cancer painrelief purpose , still complain pain level 4 Numeric Rating Scale ( NRS ) past 24 hour : Ultracet 3 tablets/day , Tramadol 150 mg/day , Codeine 200 mg /day , Codeine combination le 3 capsules/day Patients able communicate investigator his/her pain Patients use proper contraceptive study period woman childbearing potential Patients whose life expectancy 3 month long Patients sign informed consent form Patients participate clinical trial Patients history hypersensitivity opioid analgesic Patients history drug abuse Patients unable use transdermal product due skin disease Patient history CO2 retention ( e.g . chronic obstructive pulmonary disease ) Patients receive radiotherapy chemotherapy register study plan receive study Patient pregnant childbearing potential use contraceptive</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>fentanyl matrix</keyword>
</DOC>